Detalles de la búsqueda
1.
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Oncotarget
; 8(23): 37061-37079, 2017 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28427157
2.
The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
MAbs
; 6(5): 1314-26, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25517316
Resultados
1 -
2
de 2
1
Próxima >
>>